Nutrition is an important part of living well with and without hepatitis C. It is also one of the most important ingredients to help reduce the chances of developing fatty liver disease–the next liver disease epidemic. Our newly revised fact sheet provides a starting place to help people get on the right track.
Note: If there was ever a reason to treat everyone with hepatitis C just review the consequences of hepatitis C. Another reason is the potential extrahepatic manifestations, read about them here.
A recent study suggested a link between hepatitis C (HCV) infection and the development of cataracts.
The study, “Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study,” was published in the journal PLOS One.
Cataracts are a major cause of vision impairment worldwide, with an estimated prevalence of 33% in the general population. The condition is also a significant source of healthcare spending as patients with cataracts are more likely to fall, have motor vehicle accidents, and are less likely to be able to live independently, according to the researchers, from Taiwan’s China Medical University Hospital.
Liver cancers could be destroyed without the need for invasive surgery, thanks to technology being developed as part of a European project.
The EU-funded TRANS-FUSIMO project, being led by the Fraunhofer Institute for Medical Image Computing MEVIS in Bremen, is developing a technique in which high intensity focused ultrasound is used to target specific areas of the liver.
High intensity focused ultrasound uses sound waves to target a precise location in the body, generating a hot spot that can destroy diseased tissue.
Diabetes did not affect the surgical outcomes of patients with hepatitis C-related hepatocellular carcinoma following liver resection, according to results of a recently published study.
“It has been commonly understood that [diabetes] is a risk factor for the development of HCC, especially in patients with HCV infection. However, it is still controversial whether [diabetes] affects the prognosis and operative outcomes of patients with HCC,” the researchers wrote. “In the present study, [diabetes] did not appear to have a negative impact on patients’ survival after HCC resection, suggesting that [diabetes] is not an exclusion criterion for HCC surgery under good glycemic control.”
Researchers compared clinical characteristics and surgical outcomes between 112 patients with HCV-related HCC with diabetes and 112 propensity-matched patients without diabetes who underwent curative liver resection between January 2001 and December 2013.
At a time when cases of hepatitis C are on the rise in North Carolina due to the ongoing opioid epidemic, Triangle-based physicians and state officials have partnered on a new mentorship program to combat the liver disease.
The UNC School of Medicine, Duke University Medical Center and the N.C. Division of Public Health launched the Carolina Hepatitis Academic Mentorship Program (CHAMP) earlier this year. The program is currently providing “telementoring” services to roughly 30 primary care providers in the state, according to Dr. Michael Fried, professor of medicine and director of the UNC Liver Center.
“In North Carolina, acute Hepatitis C has increased 400 percent since 2009,” UNC stated in a release announcing the new partnership. “There are an estimated 110,000 people in the state living with chronic hepatitis C – a persistent liver disease that can lead to serious complications, including cirrhosis or liver cancer.”
Tuesday Mar. 21
2:00 – 3:30 p.m. ET || 1:00 – 2:30 p.m. CT || 12:00 – 1:30 p.m. MT || 11:00 – 12:30 p.m. PT
The discovery of over 200 new HIV diagnoses in Indiana’s small, rural Scott County over the course of 2015 was a major wake up call for many about the dangers of ignoring the HIV prevention needs of people who inject drugs. The massive number of new cases in Scott County coupled with the ongoing epidemic of injection drug use in rural America significantly changed the political landscape around HIV prevention in the past few years, leading the Centers for Disease Control and Prevention to identify 220 other counties that could be vulnerable to similar HIV “outbreaks.”
The situation in Scott County led to substantive policy change in December of 2015 when the Republican-led Congress quietly reversed their stance on a federal ban barring funding from being spent on syringe access programs (SAPs) – a change that had long been sought by HIV prevention advocates. How do we holistically address the needs of these communities beyond SAPs? How do we best involve affected communities within these responses?
Join Treatment Action Group, Harm Reduction Coalition, Indiana Minority Health Coalition, and Project Cultivate for a webinar that will consult with some local and state leaders in the response to the situation in southern Indiana, and discuss with Harm Reduction Coalition how best to implement a comprehensive and community-led response to HIV, Hepatitis C, and injection drug use in rural America.
HIV Prevention Research and Policy Coordinator, Treatment Action Group
Dr. Carrie Ann Lawrence
Assistant Researcher, Indiana School of Public Health – Bloomington
Project Director, Project Cultivate
Director of Public Policy & Engagement
Indiana Minority Health Coalition
Deputy Director of Planning and Policy
Harm Reduction Coalition
Note: This story is from INDIA. I have included it here because people travel overseas for pleasure travel and may have a medical emergency or travel to have surgical operations because of the cost of medical care in their home country. It’s important to know that not every country effectively screens their blood supply for blood-borne pathogens as this editorial piece points out. Alan
Although blood transfusions are considered life-saving, unsafe blood transfusions can at times be life-threatening. The latest National Aids Control Organisation (NACO)released report in response to an RTI request reveal that 14,474 cases of HIV has been caused due to unsafe blood transfusion alone in India over the last seven years. Not just this, but observations from the report also reveals that there has been a 10% rise in the number of HIV cases through blood transfusion over the last one year from 1,424 in 2014-15 to 1,559 in 2015-16. This shocking data brings to light the bitter truth that screened and tested blood available in blood banks might not always be safe after all.
These are the number of cases which have been reported. There are many more cases which don’t even come to light. Apart from HIV, other dilapidating diseases such as Hepatitis B and C can also pass through blood from an infected donor to a recipient. The news about the spread of infections through blood transfusions increasing by the day needs immediate attention.
Recent data released by Trio Health show that the prevalence of hepatitis C drug patients diagnosed with Hepatitis C but not started on curative drugs, such as Harvoni (ledipasvir/sofosbuvir; Gilead) and Zepatier (elbasvir/grazoprevir; Merck), more than tripled between 2014 and 2016—signaling that payers continue to deny coverage despite increased marketplace competition and availability of discounts.
“There are no other disease states that I’m aware of where curative therapies are increasingly withheld from patients who are covered by commercial insurance plans, Medicaid or Medicare,” Nezam Afdhal, MD, professor of medicine, Harvard University, and chairman of Trio Health’s Scientific Steering Committee, said in a press release.
According to the data, although the number of treated patients continually decreases, the total number of patients seeking treatment for their condition continues to grow each year. On average, as of last September, 37% of patients who showed little-to-moderate traces of the disease were denied—a steady increase from 27% in October 2015. Likewise, 24% of those with advanced forms of hepatitis C were also denied—an increase from 15% during 2015. Overall, non-starts increased from 8% in 2014 to over 30% in 2016.